Overview of Clocort H

Quick Facts

Property	Description
Active Ingredients	Chloramphenicol, Dexamethasone
Form	Ophthalmic/Otic Solution (Drops), Ophthalmic Ointment
Pharmacological Class	Combination Antibiotic and Corticosteroid
General Purpose	Simultaneous treatment of infection and inflammation
Origin	Synthetic

What Type of Medicine is Clocort H?

Clocort H is a prescription-only medicine classified as a fixed-dose combination product for topical administration to the eyes (ophthalmic) or ears (otic). This structural combination allows for two distinct therapeutic actions to be delivered concurrently to the affected area, facilitating the management of localized infection and inflammation at the same time. The medicine is primarily presented as an ophthalmic or otic solution (drops) and sometimes as an ophthalmic ointment. All active components are produced through chemical synthesis, classifying the medicine as a synthetic pharmaceutical entity. It is categorized within the pharmacological class of combined Antibiotic and Corticosteroid preparations.

Composition: Chloramphenicol and Dexamethasone

The identity of Clocort H is defined by its two primary active ingredients: the broad-spectrum anti-infective Chloramphenicol and the high-potency anti-inflammatory steroid Dexamethasone. Chloramphenicol functions by inhibiting the growth of susceptible bacteria. This action targets the microbial organisms directly at the source of the infection. Conversely, Dexamethasone is a glucocorticoid that functions to mitigate the body's inflammatory response, which helps reduce symptoms such as swelling and redness. This therapeutic pairing is also utilized in other formulations, such as those marketed under the brand names Decol C or Odomycetin D.

General Purpose: Dual Action for Infection and Inflammation

The general purpose of this medication is to provide intervention for conditions where a bacterial infection occurs alongside significant inflammation, such as in specific localized eye or ear issues. The primary function of this dual-action formulation is its ability to address the infectious agent via Chloramphenicol while simultaneously using Dexamethasone to manage associated symptoms such as swelling, redness, and local irritation. This approach is intended to address the underlying cause of the condition while stabilizing discomfort and reducing the visible signs of inflammation.

Regulatory References

Chloramphenicol Mechanism of Action

What side effects are possible with Clocort H?

Possible side effects and safety information

The safety profile for this topical combination of Chloramphenicol and Dexamethasone is organized by regulatory agencies, classifying potential adverse reactions by the system affected and their typical frequency.

Adverse Reaction Classification

Classification	Examples of Officially Documented Effects
Common / Transient	Ocular discomfort, stinging, burning sensation, temporary blurred vision, and redness of the conjunctiva.
Rare / Serious	Irreversible blood dyscrasias (e.g., aplastic anaemia) linked to the Chloramphenicol component.

System-Organ Classes and Serious Risks

Adverse effects are documented primarily under Eye Disorders, which include local irritation and the more serious risk of increased intraocular pressure (Glaucoma) and posterior subcapsular cataract formation. These structural ocular risks are formally associated with prolonged use of the Dexamethasone component. Other affected systems include Blood and Lymphatic System Disorders due to the rare but severe hematological potential of Chloramphenicol, and Immune System Disorders covering hypersensitivity reactions.

Population-Specific Safety Notes

The prescribing information includes specific safety constraints for vulnerable groups. The medicine is not recommended during pregnancy and is generally considered contraindicated during lactation due to the potential systemic effects of Chloramphenicol. Safety is not established for use in children under two years of age. Additionally, the label documents that patients with diabetes may face an increased risk of developing cataracts and elevated intraocular pressure.

Transient visual blurring may occur upon application, which constitutes a temporary restriction on the ability to drive or operate machinery until vision clears.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Clocort H (Chloramphenicol/Dexamethasone) is structured around the minimal likelihood of systemic overdose when the product is used topically as directed. According to official product labeling, there are no reports of overdose documented from standard application. Should too much product be applied, the most common local clinical manifestation noted from overuse is the potential for increased redness of the eye.

When to Seek Urgent Medical Attention

Due to the nature of this medicine’s components, urgent action is mandated in the event of suspected excessive exposure, particularly if the contents of the vial are accidentally ingested.

You must contact a healthcare professional, hospital emergency department, or regional poison control centre immediately. This critical action is required even if there are no symptoms are observable, to ensure rapid professional assessment.

The management of a suspected overdose is defined as being supportive in nature. In cases of accidental ingestion, procedures must be initiated to delay and reduce the extent of absorption of the active substances, as no specific antidote is known.

Element	Official Regulatory Status
Systemic Overdose Risk	Minimal likelihood from topical application.
Antidote Availability	No specific antidote is known.
Required Action	Contact emergency services immediately.

Therapeutic Uses of Clocort H

This medicine is commonly used for conditions presenting with both inflammatory states and the risk of bacterial contamination, or where a secondary bacterial infection is confirmed. This therapeutic combination is utilized for its dual supportive action in these scenarios.

Simultaneous Management of Infection and Acute Inflammation

This medication is applied in cases where symptoms related to inflammatory or irritative states are severe and co-exist with a susceptible bacterial presence. It helps address symptom clusters that include noticeable redness, swelling, and discharge in conditions presenting with acute or disruptive episodic manifestations. This support contributes to easing the overall symptom load during periods of heightened symptoms.

Support in Specialized Ocular and Otic Scenarios

The medicine is relevant for managing acute symptomatic episodes like bacterial conjunctivitis and otitis externa, and it is commonly used in specialized clinical settings such as post-operative situations. Applied during phases of increased distress or discomfort, it offers symptomatic relief that helps patients manage symptom fluctuations more steadily.

Quick Fact Block

Quick Fact: Relief for Acute Discomfort	Description
Symptom Domain	Inflammation and Infection (Dual Focus)
Clinical Relevance	Acute, symptomatic episodes; Post-operative support
Primary Benefit	Easing overall symptom load
Usage Context	Localized eye or ear issues

Eligibility and Restrictions for Use

Clocort H is subject to strict eligibility rules based on regulatory warnings for its component drugs, Chloramphenicol and Dexamethasone. Use is contraindicated (prohibited) for patients with a known hypersensitivity to any component or a personal/family history of blood disorders, including aplastic anemia [EFDA/SmPC].

Age-Related and Condition-Based Exclusions

The medicine is contraindicated in neonates (newborn infants under 28 days) due to the risk of systemic toxicity. For children under two years, use is restricted and requires prescription oversight. Intensive or prolonged therapy is also contraindicated in all children [EFDA/SmPC].

Exclusions based on local condition include viral infections like Herpes Simplex keratitis, as well as fungal or mycobacterial infections of the eye, which can be worsened by the corticosteroid [DailyMed/NDA]. Use is also restricted in patients with glaucoma or hepatic dysfunction [EFDA/SmPC].

Physiological Status

Use of Clocort H is not recommended during pregnancy or lactation due to the potential for systemic absorption of Chloramphenicol [SmPC/HPRA]. The otic solution is not recommended if the eardrum is perforated [NHS].

What should I know about interactions with other medicines?

The official regulatory interaction profile for Clocort H is structured around the pharmacokinetic and pharmacodynamic properties of its two active components.

Metabolic Pathway Alterations and Exposure Risk

Co-administration with strong CYP3A4 inhibitors (e.g., Ritonavir, Cobicistat) may increase the systemic exposure of the Dexamethasone component, which regulatory documents formally link to an increased risk of Adrenal Suppression or Cushing's Syndrome. Conversely, strong CYP3A4 Inducers (e.g., Rifampicin, Phenytoin) may reduce the plasma concentration and therapeutic efficacy of Dexamethasone. The Chloramphenicol component is a known enzyme inhibitor that can increase the blood levels of co-administered drugs.

Additive Toxicological and Pharmacodynamic Risk

Official warnings advise against co-administration with other Myelosuppressive Medications, as this carries a heightened, additive risk of severe Bone Marrow Depression associated with the Chloramphenicol component. The use of Live Bacterial Vaccines is a major restriction due to the known immunosuppressive effects of Dexamethasone. Furthermore, the label notes that simultaneous use of the Dexamethasone component with Anticholinergics (e.g., Atropine) may increase the risk of elevated intraocular pressure.

Procedural and Population Constraints

Regulatory documents specify that when administering this medicine concurrently with other topical ophthalmic preparations, a minimum separation interval of at least 5 minutes must be observed between applications. Population-specific cautions include the heightened risk of Dexamethasone systemic effects in Pediatric Patients when used with CYP3A4 inhibitors, and warnings for use in patients with impaired Hepatic or Renal Function due to the potential for Chloramphenicol accumulation.

Mechanism of Action

Direct Activation of the Glucocorticoid Receptor

Clocort H's active components function as agonists for the intracellular Glucocorticoid Receptor (GR) in target cells. This binding causes a conformational change in the receptor, which then translocates to the nucleus to influence the cell's genetic machinery. This initial molecular action establishes the comprehensive anti-inflammatory cascade that follows.

Suppression of Pro-Inflammatory Gene Expression

The GR-drug complex modulates key regulatory pathways through two actions. Via transrepression, it suppresses the function of pro-inflammatory transcription factors, such as Nuclear Factor kappa B ( NF-kappa B). Via transactivation, it induces the expression of anti-inflammatory proteins, notably Lipocortin-1. This protein inhibits the enzyme Phospholipase A2 ( PLA2), thereby limiting the synthesis of prostaglandins and leukotrienes via the Arachidonic Acid Cascade. This modulation results in a reduction in the biochemical signals responsible for inflammation.

Modulating Local Vascular and Immune Responses

As a consequence of decreased mediator production, the mechanism causes localized vasoconstriction (narrowing of local blood vessels) and a decrease in capillary permeability at the site of application. These physical adjustments, coupled with the inhibition of immune cell migration, result in physiological changes characterized by the limiting of blood flow and fluid extravasation, affecting local erythema and edema.

Dosage and Administration Information

How to Use Clocort H

Clocort H is intended for topical administration as a solution (drops) or ointment, specifically for use in the eyes (ocular) or ears (auricular). The administration involves specific parameters regarding the quantity, frequency, duration, and method of application.

Labeled Dosing and Frequency

For ocular use, the standard adult regimen involves instilling one drop into the affected eye(s) three to five times daily. In scenarios requiring high initial delivery, the frequency may be increased to one drop every hour. The initial dosing for the otic solution typically involves administering two to three drops several times daily, with the frequency decreasing as the condition improves.

Course Duration and Procedural Steps

The total duration of treatment typically does not exceed 10 days. The administration frequency is generally reduced gradually rather than stopped abruptly.

During ocular application, the drops are instilled into the conjunctival sac. A key procedural step is to press the nasolacrimal duct (the inner corner of the eye) with a finger for two to three minutes immediately after installation to limit systemic absorption. Furthermore, if other topical eye medications are used, their application is separated by a minimum of five minutes.

Population-Specific Rules

While no dose adjustment is required for older adults (over 65 years), use in the pediatric population is restricted: the medicine is not recommended for infants less than 28 days old, and its use in children up to two years is generally reserved for exceptional cases.

Recent Clinical Evidence

Research evidence / Overview of Studies for Clocort H

The research base for this fixed-dose combination, which includes the antibiotic Chloramphenicol and the corticosteroid Dexamethasone, is structured around clinical trials and analyses that explored external infections associated with inflammation in the eye and ear. The evidence available typically includes data from short-term Randomized Controlled Trials (RCTs) and peer-reviewed scientific literature.

Evidence for Use in Acute Bacterial Conjunctivitis

Research was studied for conditions where a bacterial infection was associated with inflammation in the eye. This research was conducted primarily through short-term RCTs and Systematic Reviews that focused on topical antibiotics, often compared to a placebo or another antimicrobial class. Study populations usually include a mix of adults and children (typically aged six months and older).

Studies monitored outcomes related to physical discomfort and inflammatory or irritative states, such as redness, swelling, and discharge, over defined time intervals. The main outcomes research examined were measurements of Clinical Cure (the resolution of visible signs) and Microbiological Cure (the clearance of the targeted bacteria).

Evidence for Use in Acute Otitis Externa

The research was evaluated in settings of Acute Otitis Externa (AOE) in the ear canal. Studies monitored patient-reported outcomes describing perceived discomfort like pain, alongside outcomes linked to inflammatory or irritative states such as swelling and discharge. Findings describe patterns observed in the studies of AOE where antibiotic-steroid combinations were compared to single agents. These results apply only to the populations studied, which typically included patients with uncomplicated diffuse AOE.

What is Still Uncertain About Clocort H

Key limitations include the inherent difficulty in isolating the effect of the added corticosteroid (Dexamethasone) from the core anti-infective effect (Chloramphenicol) in many clinical settings. Follow-up durations were limited, and long-term outcomes, such as recurrence rates beyond a few weeks, are not fully established by the existing studies. The high rate of spontaneous symptom resolution in placebo groups for acute conjunctivitis means that research does not determine whether an individual will respond similarly to the group pattern.

Frequently Asked Questions (FAQ)

Common questions about Clocort H (FAQ)

Q: Does Clocort H help with itching or just the inflammation?

The Dexamethasone component in Clocort H is a potent anti-inflammatory agent. By working to reduce redness, swelling, and irritation, it helps to resolve the inflammation that causes discomfort, including related itching.

Q: Can I use Clocort H if I'm also taking an oral antihistamine?

Specific interactions with oral antihistamines are generally not highlighted in the product’s official regulatory documentation. However, due to the potential for generalized drug-drug interactions, it is important for a healthcare provider to be aware of all medicines being taken.

Q: Can older adults use Clocort H without higher risk?

Official information indicates that no dose adjustment is typically required for older adults (over 65 years). Despite this, the product label mentions that the systemic effects of the Dexamethasone component may be more pronounced in this population.

Q: Do I need to wash my hands immediately after applying Clocort H?

Yes. Standard administration practice for this type of ophthalmic and otic medication involves washing hands with soap and water before and immediately after application to help prevent contamination and unintentional exposure.

Q: Is it possible to have an allergic reaction to Clocort H?

Yes, it is possible to have an allergic reaction. Official regulatory documents list hypersensitivity reactions as a potential adverse effect. The medicine is contraindicated (prohibited) for patients with a known hypersensitivity to any of its components.

Q: How does the 'H' part in Clocort H differ from a regular Clocort cream?

The 'H' often denotes the Dexamethasone component in the fixed-dose combination. This indicates that Clocort H is specifically a combination product containing both an anti-infective and a powerful steroid, intended only for use in the eye or ear.

Q: Is it possible for Clocort H to cause pigment changes (lightening or darkening) in the skin?

Clocort H is only approved for use in the eyes or ears, not for general skin use. However, the corticosteroid component (Dexamethasone) belongs to a class of drugs that, when used topically on the skin for long periods, has been associated with changes in skin pigmentation (such as lightening).

Q: How long does the effect of one application of Clocort H typically last?

The official dosing frequency for ocular use typically requires several applications throughout the day. This suggests that one application is intended to cover a span of several hours before the next scheduled dose.

Q: Are there any specific foods or drinks that interact with Clocort H?

Since Clocort H is applied topically to the eye or ear, clinically significant food or drink interactions are generally not expected. However, patients with certain conditions must be aware of potential systemic absorption effects, which can sometimes have food or drink considerations for other steroid types.

Q: Is Clocort H effective for treating insect bites?

No. Clocort H is only approved for specific conditions in the eyes and ears that involve bacterial infection and inflammation. It is not indicated for treating general skin issues like insect bites.

Q: How often can I safely reapply Clocort H in one day?

The standard application frequency for adult ocular use is typically detailed in the official product information. In certain clinical situations, the product information may allow for a temporary increase in frequency, which requires close supervision by a healthcare professional.

Q: Can using too much Clocort H lead to systemic absorption side effects?

Yes. Regulatory warnings indicate that excessive use or over-absorption of the medication can lead to systemic side effects from the Dexamethasone component, such as Adrenal Suppression. Absorption of the Chloramphenicol component also carries a risk of rare, serious effects documented in the product label.

Q: Is it okay to use Clocort H on broken or wounded skin?

Official documentation states the otic solution is not recommended if the eardrum is perforated (broken). Furthermore, caution is advised, as applying the medication to broken skin or severe wounds at the site of application could increase systemic absorption.

Q: Can Clocort H be used on the face for a short time?

Clocort H is approved strictly for ocular (eye) or otic (ear) use. It is not indicated for general skin application on the face or body.

Q: What is the longest continuous period someone usually uses Clocort H?

Official regulatory documents specify that the total duration of treatment with Clocort H should generally not exceed 10 days. This duration is consistent with usage guidelines designed to minimize the risk of side effects associated with prolonged use of corticosteroids.

Q: Is it normal to feel a slight burning sensation when first applying Clocort H?

Yes. Ocular discomfort, stinging, and a burning sensation are officially documented as common and transient side effects that may occur immediately upon application.

Q: What happens if I stop using Clocort H suddenly after using it for a while?

The official product information specifies that the administration frequency is to be reduced gradually rather than stopped abruptly, aligning with standard principles for using topical steroids. This gradual reduction is consistent with the general usage principles for topical steroids.

Q: Can Clocort H affect my blood sugar levels, especially if I have diabetes?

Regulatory warnings mention that patients with diabetes may have an increased risk of developing cataracts and elevated intraocular pressure. Although a direct effect on systemic blood sugar is not typically noted for topical use, patients with diabetes may have an increased risk of developing cataracts and elevated intraocular pressure, according to regulatory warnings.

Q: How should Clocort H cream be stored at home?

Official labeling requires that the ophthalmic solution be refrigerated between 2 C and 8 C and protected from light. After the container is first opened, the solution must be discarded within 28 days.

Q: Is Clocort H safe for use during pregnancy or while breastfeeding?

Official product information states that Clocort H is not recommended during pregnancy and is generally considered contraindicated during lactation. This caution is cited due to the potential for systemic absorption of the Chloramphenicol component.

Q: Can I apply makeup or sunscreen after using Clocort H on my face?

Clocort H is only approved for use in the eyes or ears, not for general use on the face or skin. If the drops are administered to the eye, the administration protocol specifies that application of any other topical ophthalmic preparations should be separated by a minimum interval of five minutes.

How should Clocort H be stored and disposed of?

Required Storage and Stability

Official labeling requires Clocort H ophthalmic solution to be refrigerated at a temperature between 2 C and 8 C (36 F and 46 F), and it must be protected from light. Freezing of the medicine is prohibited to maintain its stability.

After the container is first opened, the remaining solution has a limited shelf-life and must be discarded after 28 days, regardless of how much medicine remains. The container should be kept tightly closed when not in use.

Handling and Disposal

All medicine must be stored out of the sight and reach of children.

Disposal of any unused, expired, or leftover product must be managed in accordance with local requirements for medicinal waste. Patients should consult a healthcare professional for specific disposal guidance, as environmental release must be avoided.

Clocort H